NICE 首部心脏瓣膜病指南解读:与欧美学会指南的差异与启示
本文解读英国 NICE 于 2021 年底发布的首部成人心脏瓣膜病诊疗指南,并将其与 2020 年 ACC/AHA 和 2021 年 ESC/EACTS 学会指南进行对比。NICE 指南面向英国国家医疗服务体系,兼顾临床效果与成本效益,因此在有症状重度主动脉瓣狭窄等治疗推荐上与欧美指南存在差异。
要点
- NICE 首部成人心脏瓣膜病指南于 2021 年底发布,聚焦检查与管理。
- NICE 指南需兼顾成本效益,与欧美学会指南存在差异。
- 有症状重度主动脉瓣狭窄的治疗推荐差异源于成本影响。
核心结论
- NICE 指南与欧美学会指南在部分推荐上存在差异,尤其是有症状重度主动脉瓣狭窄的治疗。
- 差异主要源于 NICE 需兼顾英国国家医疗服务体系的成本效益。
- 本文旨在概述 NICE 指南范围与推荐,并比较其与学会指南的异同及优劣。
研究设计与样本
- 本文为综述性解读文章,概述 NICE 指南的范围与推荐,并与 ACC/AHA 2020 和 ESC/EACTS 2021 指南进行比较。
主要发现
- NICE 指南与欧美学会指南在推荐上存在差异,尤其体现在有症状重度主动脉瓣狭窄的治疗。
- NICE 明确说明成本因素影响了其最终推荐,导致与欧美指南不同。
临床怎么用
- 临床医生应了解 NICE 指南与欧美学会指南的差异及其成本效益考量背景。
- 在解读和应用指南时,需结合当地医疗体系与患者具体情况。
局限性
- 本文为综述性解读,未报告原始研究数据或系统评价。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
The National Institute for Health and Care Excellence (NICE) guidelines are evidence-based recommendations for health and care in England. In late 2021, NICE published its first ever guidance on the investigation and management of adults with heart valve disease. This followed on from recent updates to the international societal practice guidelines on heart valve disease produced by the American College of Cardiology and American Heart Association (in 2020) and the European Society of Cardiology and European Association for Cardiothoracic Surgery (in 2021). The purpose of the NICE guidance has significant differences from societal guidelines, as NICE guidance is designed for implementation within the UK's taxpayer-funded National Health Service and thus must account not just for clinical effectiveness of treatments but cost-effectiveness also. This explains some of the differences between recent recommendations from these bodies, most notably in the treatment of patients with symptomatic severe aortic stenosis, in which NICE clearly explains that cost implications influenced their final guidance (which differs from the recently published European and North American guidelines). The aims of this review article are to provide an overview of the scope and recommendations of the NICE guideline and to compare and contrast the guidelines, highlighting reasons for differences between the guidance from professional societies and NICE and discussing the relative strengths and weaknesses of the NICE guideline.
引用
- Shah BN. National Institute for Health and Care Excellence (NICE) guidance on heart valve disease. Heart. 2023. PMID: 36653169. doi:10.1136/heartjnl-2022-321095
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。